Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .
Hemodynamic, Hemorheologic, and Hemocoagulative Changes After Treatment With Picotamide in Patients Affected by Peripheral Arterial Disease (PAD) of the Lower Limbs
Effects of picotamide on platelet activity and on some hemorheologic , coagu lative , and hemodynamic parameters were investigated in a r and omized , dou ble-blind , placebo-controlled study for eighteen months . Twenty patients , average age 61.5±9.6 ( SD ) years , with peripheral arterial disease ( PAD ) at functional stage 2 of the Fontaine classification and with intermittent claudica tion for at least six months were studied . Ten patients received tablets of picotamide , 300 mg three times a day , and 10 subjects received three identical placebo tablets each day . Similar atheroscler otic disease risk factors were present in both groups . Picotamide induced a significant decrease of plasma viscosity , fibrinogen , and beta-thromboglobulin and an increase of amplitude of the photoplethysmo graphic wave
Antiplatelet agents have a beneficial effect in reducing all cause mortality and fatal cardiovascular events in patients with IC .
BACKGROUND Peripheral arterial disease ( PAD ) is common and is a marker of systemic atherosclerosis .
Patients with symptoms of intermittent claudication ( IC ) are at increased risk of cardiovascular events ( myocardial infa rct ion ( MI ) and stroke ) and of both cardiovascular and all cause mortality .
OBJECTIVES To determine the effectiveness of antiplatelet agents in reducing mortality ( all cause and cardiovascular ) and cardiovascular events in patients with intermittent claudication .